169 related articles for article (PubMed ID: 17020999)
1. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
[TBL] [Abstract][Full Text] [Related]
2. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Rendi MH; Suh N; Lamph WW; Krajewski S; Reed JC; Heyman RA; Berchuck A; Liby K; Risingsong R; Royce DB; Williams CR; Sporn MB
Cancer Res; 2004 May; 64(10):3566-71. PubMed ID: 15150113
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Suh N; Lamph WW; Glasebrook AL; Grese TA; Palkowitz AD; Williams CR; Risingsong R; Farris MR; Heyman RA; Sporn MB
Clin Cancer Res; 2002 Oct; 8(10):3270-5. PubMed ID: 12374698
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
Liby K; Risingsong R; Royce DB; Williams CR; Yore MM; Honda T; Gribble GW; Lamph WW; Vannini N; Sogno I; Albini A; Sporn MB
Clin Cancer Res; 2008 Jul; 14(14):4556-63. PubMed ID: 18628471
[TBL] [Abstract][Full Text] [Related]
5. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.
Mazumdar A; Medina D; Kittrell FS; Zhang Y; Hill JL; Edwards DE; Bissonnette RP; Brown PH
Cancer Prev Res (Phila); 2012 Oct; 5(10):1195-202. PubMed ID: 22926341
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
[TBL] [Abstract][Full Text] [Related]
7. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Shen Q; Kim HT; Xu X; Hilsenbeck SG; Bissonnette RP; Lamph WW; Brown PH
Clin Cancer Res; 2007 Oct; 13(20):6224-31. PubMed ID: 17947490
[TBL] [Abstract][Full Text] [Related]
8. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Wu L; Tannock IF
Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
[TBL] [Abstract][Full Text] [Related]
9. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
[TBL] [Abstract][Full Text] [Related]
10. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.
Liby K; Royce DB; Risingsong R; Williams CR; Wood MD; Chandraratna RA; Sporn MB
Clin Cancer Res; 2007 Oct; 13(20):6237-43. PubMed ID: 17947492
[TBL] [Abstract][Full Text] [Related]
11. Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia.
Lemieux C; Gélinas Y; Lalonde J; Labrie F; Richard D; Deshaies Y
Metabolism; 2006 May; 55(5):605-13. PubMed ID: 16631436
[TBL] [Abstract][Full Text] [Related]
12. The selective estrogen receptor modulator acolbifene reduces cholesterolemia independently of its anorectic action in control and cholesterol-fed rats.
Lemieux C; Gélinas Y; Lalonde J; Labrie F; Richard D; Deshaies Y
J Nutr; 2005 Sep; 135(9):2225-9. PubMed ID: 16140902
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene.
Lemieux C; Phaneuf D; Labrie F; Giguère V; Richard D; Deshaies Y
Int J Obes (Lond); 2005 Oct; 29(10):1236-44. PubMed ID: 15925950
[TBL] [Abstract][Full Text] [Related]
14. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
15. Arzoxifene: the development and clinical outcome of an ideal SERM.
Munster PN
Expert Opin Investig Drugs; 2006 Mar; 15(3):317-26. PubMed ID: 16503767
[TBL] [Abstract][Full Text] [Related]
16. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
17. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado Martín PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
20. Prevention of breast cancer by newer SERMs in the future.
Powles T
Recent Results Cancer Res; 2011; 188():141-5. PubMed ID: 21253796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
